中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
7期
43-43,45
,共2页
派罗欣%利巴韦林%Ⅰb型慢性丙肝
派囉訢%利巴韋林%Ⅰb型慢性丙肝
파라흔%리파위림%Ⅰb형만성병간
Pegasys%Ribavirin%Ⅰb chronic hepatitis C
目的：探究派罗欣联合利巴韦林抗病毒治疗对Ⅰb 型慢性丙肝的临床疗效观察。方法：对照组给予干扰素-α-1b联合利巴韦林治疗，观察组给予派罗欣联合利巴韦林治疗，观察对比两组临床疗效、复发情况及药物不良反应情况。结果：观察组早期应答率86.5%，明显高于对照组的70.3%，P＜0.05；观察组无效率5.4%，复发率5.4%，均分别低于对照组的24.3%和18.9%，组间比较差具有统计学意，P均＜0.05。两组不良反应比较差异无统计学意义， P＞0.05。结论：派罗欣联合利巴韦林治疗Ⅰb型慢性丙肝病毒的临床疗效确切，早期应答率较高，复发率较低，且用药安全，可作为临床首选治疗方案。
目的：探究派囉訢聯閤利巴韋林抗病毒治療對Ⅰb 型慢性丙肝的臨床療效觀察。方法：對照組給予榦擾素-α-1b聯閤利巴韋林治療，觀察組給予派囉訢聯閤利巴韋林治療，觀察對比兩組臨床療效、複髮情況及藥物不良反應情況。結果：觀察組早期應答率86.5%，明顯高于對照組的70.3%，P＜0.05；觀察組無效率5.4%，複髮率5.4%，均分彆低于對照組的24.3%和18.9%，組間比較差具有統計學意，P均＜0.05。兩組不良反應比較差異無統計學意義， P＞0.05。結論：派囉訢聯閤利巴韋林治療Ⅰb型慢性丙肝病毒的臨床療效確切，早期應答率較高，複髮率較低，且用藥安全，可作為臨床首選治療方案。
목적：탐구파라흔연합리파위림항병독치료대Ⅰb 형만성병간적림상료효관찰。방법：대조조급여간우소-α-1b연합리파위림치료，관찰조급여파라흔연합리파위림치료，관찰대비량조림상료효、복발정황급약물불량반응정황。결과：관찰조조기응답솔86.5%，명현고우대조조적70.3%，P＜0.05；관찰조무효솔5.4%，복발솔5.4%，균분별저우대조조적24.3%화18.9%，조간비교차구유통계학의，P균＜0.05。량조불량반응비교차이무통계학의의， P＞0.05。결론：파라흔연합리파위림치료Ⅰb형만성병간병독적림상료효학절，조기응답솔교고，복발솔교저，차용약안전，가작위림상수선치료방안。
Objective:To explore the clinical efficacy of pegasys and ribavirin antiviral therapy for chronic hepatitis C in Ⅰb. Methods:The control group received-α-1b interferon and ribavirin,the observation group received pegasys and ribavirin,two groups were observed and compared the clinical efficacy,recurrence and adverse drug reactions.Results:Early response rate of the observation group was 86.5%,significantly higher than the control group 70.3%,P<0.05;the ineffective rate of the observation group was 5.4%,the recurrence rate was 5.4%,were lower than those in the control group 24.3% and 18.9%,there was statistically significant,P<0.05.There is no significant difference between two groups of adverse reaction,P>0.05.Conclusion:There is good clinical efficacy of pegasys and ribavirin antiviral therapy for chronic hepatitis C in Ⅰ b,early response rate is higher,the recurrence rate is low,and the safety of drug use,can be used as the preferred clinical treatment.
